ClinicalTrials.gg
RecruitingNCT04778046PH SOLARUpdated Feb 24, 2026

Pulmonary Hypertension SOLAR

A Phase 2 interventional study of Hyperpolarized 129Xe in Interstitial Lung Disease, COPD and Pulmonary Arterial Hypertension, sponsored by Bastiaan Driehuys. Recruiting at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-24.

Sponsored by Bastiaan Driehuys · Phase 2, Interventional, and Diagnostic

How we know

From the registry’s dates

  • Started Nov 2023; still recruiting 3 years later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
30
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 201 studies in Lung Diseases, Interstitial with a site in United States — 67 open to participants now, 83 under way, 19 of them phase 3. Lung Diseases, Interstitial · United States.

Planned enrollment
91st of 138
30 · median 53
Started
2023
with 19 others
Phase 2
52 of 201
21 open now
Primary completion
2027-07
later than 24 of 82 live
Registered
108th of 201
by date
Lead sponsor
4 of 201
Bastiaan Driehuys

Among the 201 studies in Lung Diseases, Interstitial with a site in United States, this one is the 91st largest by planned enrollment of the 138 interventional ones that give a count, is one of 20 that started in 2023, is one of 52 in phase 2, reaches primary completion later than 24 of the 82 other live ones, and was the 108th registered.

Lung Diseases, Interstitial

682 studies on the registry are indexed under Lung Diseases, Interstitial; 245 are open to participants now.

Browse Lung Diseases, Interstitial studies →

Open to participants now

67 of the 201 studies in Lung Diseases, Interstitial with a site in United States are open now. Recruiting first, the newest first:

62 more — sign in →

All 67 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 172 Lung Diseases, Interstitial studies recruiting now, 108 (63%) set no upper age limit and 25 (15%) stop at 75 or younger; 13 take children under 18; 21 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 201 studies in Lung Diseases, Interstitial with a site in United States, or all of them as a file.
02

Study summary

The main goal of this study is to develop a noninvasive signature for pulmonary vascular remodeling in Group 3 PH patients, using hyperpolarized 129Xe magnetic resonance imaging (129Xe MRI). Such a signature may identify Group 3 PH responders to PAH-specific therapies. PAH's unique 129Xe MRI signature has been shown in previous studies. Past studies have lacked a pathologic "ground truth" correlate of these signatures, which could be provided by comparing them with the pathology of lung explant tissue from patients who have undergone a lung transplant. This signature could be validated in a cohort of patients with Group 3 PH in future studies.

Read the detailed description

The objective of this study is to identify a 129Xe MRI signature associated with PAH-like pulmonary vascular remodeling, consisting of plexiform arteriopathy, smooth muscle cell proliferation, and vascular fibrosis, in IPF and COPD that could be used to identify potential responders vs non-responders to PAH-specific therapies. The central hypothesis is that similar mechanisms and pathways underlie pulmonary vascular remodeling in IPF-PH, COPD-PH, and PAH. However, only a subset of Group 3 PH patients display remodeling consistent with PAH, resulting in responder vs. non-responder phenotypes when treated with PAH-specific therapies. In preliminary studies of subjects treated with Tyvaso, The study team has observed distinct 129Xe MRI signatures at baseline and with therapy depending on patients' underlying lung function. Consistent with this, recent studies using single-cell RNA sequencing (scRNAseq) of the pulmonary vasculature in IPF have demonstrated changes consistent with vascular remodeling.

03

Conditions studied

  • Interstitial Lung Disease
  • COPD
  • Pulmonary Arterial Hypertension

Keywords

  • Lung Transplant
  • Group 3 PH
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Age ≥ 18 years' old
  2. Be on the lung transplant waiting list at Duke University Medical Center.
  3. PH as defined by RHC - mPAP > 20 mmHg, PVR > 3 WU, PCWP \< 15 mmHg
  4. Groups defined as:

    PAH: Clinical diagnosis of PAH (Group 1 PH) in the absence of severe chronic lung disease, left heart disease, chronic thromboembolism, sarcoidosis, sickle cell disease, or other causes of non-Group 1 PH.

    -noPH: Clinical diagnosis of COPD in the absence of precapillary PH.

    COPD-PH: Clinical diagnosis of COPD with precapillary PH.

    IPF-noPH: Clinical diagnosis of IPF in the absence of precapillary PH.

    IPF-PH: Clinical diagnosis of IPF with precapillary PH.

  5. Willing and able to give and adhere to visit/protocol schedules (consent must be given before any study procedures are performed).

Exclusion criteria

Exclusion Criteria:

  1. Moderate to severe heart disease ( \< 45% or severe LV Hypertrophy).
  2. Sarcoidosis.
  3. Active cancer.
  4. Sickle cell anemia.
  5. Liver disease (Childs-Pugh class C).
  6. Prisoners and pregnant women will not be approached for the study.
  7. Inability to obtain consent.
  8. Conditions that will prohibit MRI scanning (metal in eye, claustrophobia, inability to lie supine).
  9. Medical or psychological conditions which, in the opinion of the investigator, might create undue risk to the subject or interfere with the subject's ability to comply with the protocol requirements
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

05

Study design

Phase
Phase 2
Primary purpose
Diagnostic
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
30 participants (estimated)

Study arms

  • Experimental
    PAH:

    Clinical diagnosis of PAH (Group 1 PH) in the absence of severe chronic lung disease, left heart disease, chronic thromboembolism, sarcoidosis, sickle cell disease or other causes of non-Group 1 PH.

    Drug: Hyperpolarized 129Xe

  • Experimental
    COPD-noPH

    Clinical diagnosis of COPD in the absence of precapillary PH.

    Drug: Hyperpolarized 129Xe

  • Experimental
    COPD-PH

    Clinical diagnosis of COPD with precapillary PH

    Drug: Hyperpolarized 129Xe

  • Experimental
    IPF-noPH

    Clinical diagnosis of IPF in the absence of precapillary PH

    Drug: Hyperpolarized 129Xe

  • Experimental
    IPF-PH

    Clinical diagnosis of IPF with precapillary PH

    Drug: Hyperpolarized 129Xe

Interventions

  • DrugHyperpolarized 129Xe

    Each xenon dose will be limited to a volume less than 25% of subject lung capacity (TLC),

    Also known as: Xe MRI

06

What researchers measure

Primary outcomes

  1. a pathology-based 129Xe MRI noninvasive signature of pulmonary vascular remodeling that could be validated in a larger cohort of Group 3 PH patients

    Such a signature could then be tested in clinical trials in Group 3 PH. These studies will have an important positive impact because they lay the foundation for a precision medicine strategy in Group 3 PH through the identification of potential responders and non-responders to PAH-specific therapies

    Time frame: Day 1

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2023 (actual). Primary completion is estimated for Jul 2027, 44 months after the start.

Of 53 phase 2 interventional studies under Lung Diseases, Interstitial, half reached primary completion within 51 months of starting (the median), counting those still running; a quarter within 30 and three quarters within 71. This study's planned 44 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 26, 2021
First posted
Mar 2, 2021
StartActual
Nov 8, 2023
Primary completionEst.
Jul 31, 2027
CompletionEst.
Jul 31, 2028
Last update
Feb 24, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 24, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT04778046
Lead sponsor
Bastiaan Driehuys
Responsible party
Bastiaan Driehuys (Associate Professor of Radiology, Duke University) — Sponsor-investigator
First posted
Mar 2, 2021
Start date
Nov 8, 2023
Primary completion
Jul 31, 2027 (estimated)
Completion
Jul 31, 2028 (estimated)
Last update
Feb 24, 2026

Study contacts

Claudia Salazar
Contact
claudia.salazar@duke.edu
+1 919 660 2026
Sudarshan Rajagopal, MD, PhD
principal investigator · Duke University

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion